P2–P3 conformationally constrained ketoamide-based inhibitors of cathepsin K
David G. Barrett, Virginia M. Boncek, John G. Catalano et al. · Bioorganic & Medicinal Chemistry Letters · 2005
Cited by 34 works. doi:10.1016/j.bmcl.2005.05.062
Authors
- David G. Barrett
- Virginia M. Boncek
- John G. Catalano
- David N. Deaton
- Anne M. Hassell
- Cynthia H. Jurgensen
- Stacey T. Long
- Robert B. McFadyen
- Aaron B. Miller
- Larry R. Miller
- J. Alan Payne
- Vicente A. Samano
- Lisa M. Shewchuk
- Francis X. Tavares
- Kevin J. Wells‐Knecht
- Derril H. Willard
- Lois L. Wright
- Huiqiang Zhou
References
- Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency
- Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
- MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening
- Cortisol Modulation of Osteoblast Metabolic Activity in Cultured Neonatal Rat Bone
- Forecasting the Oral Absorption Behavior of Poorly Soluble Weak Bases Using Solubility and Dissolution Studies in Biorelevant Media
- Direct action of the parathyroid hormone-like human hypercalcemic factor on bone.
- Potent and Selective Inhibition of Human Cathepsin K Leads to Inhibition of Bone Resorption In Vivo in a Nonhuman Primate
- Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL).
- Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio
- Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor κB ligand (RANKL)